RxDoctor Payments Data

John Ciccone, MD

Cardiovascular Disease · Mt. Pleasant, SCNPI 1750378824

Payments from drug & device makers

$4,353in general payments, 2019–2025

Across 244 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$691
  • Pfizer$646
  • Johnson & Johnson$407
  • Medtronic$293
  • Boston Scientific$267
  • AstraZeneca$240
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,339100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,353 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$191,415
Medicare patients
1,729
Services billed
2,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$125,338
EntrestoSacubitril/Valsartan57$69,913
Repatha SureclickEvolocumab46$53,628
JardianceEmpagliflozin32$29,942
XareltoRivaroxaban13$14,866
Repatha SyringeEvolocumab12$10,494
Metoprolol Succinate247$2,757
Ezetimibe81$2,278
Atorvastatin Calcium159$1,820
Ranolazine ErRanolazine24$1,757
Rosuvastatin Calcium104$1,523
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,217
Valsartan35$1,143
Telmisartan49$1,078
Amlodipine Besylate101$639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$646$125,338112 claims
NovartisEntresto$96$69,91357 claims
Boehringer IngelheimJardiance$140$29,94232 claims
Johnson & JohnsonXarelto$407$14,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Mt. Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →